![]() | Only 14 pages are availabe for public view |
Abstract Psoriasis is a common, chronic inflammatory skin disease associated with multi-system manifestations including arthritis and obesity. It is a complex multifactorial condition related to a combination of genetic, environmental and immunological factors . Psoriasis is one of the most common human skin that affects 1.3-2.2% of the world population It is characterized by excessive growth and aberrant differentiation of keratinocytes, but is fully reversible with appropriate therapy. The trigger of the keratinocyte response is thought to be activation of the cellular immune system, with T cells, dendritic cells and various immune-related cytokines and chemokines implicated in pathogenesis. The newest therapies for psoriasis target its immune components and may predict potential treatments for other inflammatory human diseases. It represents a clinically heterogeneous disease, with clearly defined clinical subtypes including chronic plaque (or psoriasis vulgaris), guttate psoriasis, and generalised or localised (pustular) psoriasis. The chronic plaque form is most common (85–90%) and the clinical manifestations include well-demarcated, symmetrical erythematous plaques with adherent silvery scale. Common affected sites include the scalp, elbows, knees and pre-sacral area of the back. Nail involvement is common and psoriatic arthritis is recognised in approximately 30% of people with psoriasis PASI score is the most widely used tool for assessment of the severity of psoriasis Cluster of Differentiation 93 (CD93) is a C-type lectin-like domain (CTLD) containing glycoprotein expressed on endothelial cells, stem cells, platelets and a variety of leukocytes. CD93 belongs to the group XIV family of transmembrane glycoproteins, which are characterized by similar molecular structure including a CTLD, a series of epidermal growth factor (EGF) -like repeats and a highly glycosylated mucin domain. CD93 is located on chromosome 20 |